ECSP20034868A - Conjugados anticuerpo anti-cd40-fármaco - Google Patents

Conjugados anticuerpo anti-cd40-fármaco

Info

Publication number
ECSP20034868A
ECSP20034868A ECSENADI202034868A ECDI202034868A ECSP20034868A EC SP20034868 A ECSP20034868 A EC SP20034868A EC SENADI202034868 A ECSENADI202034868 A EC SENADI202034868A EC DI202034868 A ECDI202034868 A EC DI202034868A EC SP20034868 A ECSP20034868 A EC SP20034868A
Authority
EC
Ecuador
Prior art keywords
antibody conjugates
drug antibody
antibody
formula
drug conjugates
Prior art date
Application number
ECSENADI202034868A
Other languages
English (en)
Inventor
Jason Z Oh
Christopher C Marvin
Michael J Mcpherson
Axel Hernandez
Adrian D Hobson
Shaughn H Bryant
Ling C Santora
Lu Wang
Olivia A Perng
Wendy Waegell
Claire L Ihle
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of ECSP20034868A publication Critical patent/ECSP20034868A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

En la presente se proporcionan conjugados anticuerpo anti-CD40-fármaco que comprenden un radical de la Fórmula (I), en donde R1, R2 y R3 son como se definen en la presente. Además se proporcionan conjugados anticuerpo anti-CD40-fármaco de la Fórmula (II), en donde Z, R, AA1, AA2, AA3, m, p, q, n, w, R1, R2 y R3 son como se definen en la presente. Además se proporcionan composiciones farmacéuticas y kits de estas, y métodos para usarlos.
ECSENADI202034868A 2017-12-01 2020-06-29 Conjugados anticuerpo anti-cd40-fármaco ECSP20034868A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762593807P 2017-12-01 2017-12-01
US201762595045P 2017-12-05 2017-12-05

Publications (1)

Publication Number Publication Date
ECSP20034868A true ECSP20034868A (es) 2020-08-31

Family

ID=66663861

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202034868A ECSP20034868A (es) 2017-12-01 2020-06-29 Conjugados anticuerpo anti-cd40-fármaco

Country Status (19)

Country Link
US (1) US20220265842A1 (es)
EP (1) EP3716982A4 (es)
JP (1) JP2021504430A (es)
KR (1) KR20200095493A (es)
CN (1) CN111465399A (es)
AU (1) AU2018374633A1 (es)
BR (1) BR112020010691A2 (es)
CA (1) CA3081559A1 (es)
CL (1) CL2020001442A1 (es)
CR (1) CR20200285A (es)
DO (1) DOP2020000119A (es)
EC (1) ECSP20034868A (es)
IL (1) IL274650A (es)
MX (1) MX2020005465A (es)
PE (1) PE20201464A1 (es)
PH (1) PH12020550551A1 (es)
RU (1) RU2020117156A (es)
SG (1) SG11202004865SA (es)
WO (1) WO2019106608A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021013174A2 (pt) * 2019-01-11 2021-11-03 Novartis Ag Anticorpos anti-cd40 para uso no tratamento da hidradenite supurativa
JP2024506012A (ja) * 2021-02-04 2024-02-08 上海森▲輝▼医▲葯▼有限公司 グルココルチコイド受容体アゴニストの薬物複合体及びその医薬的応用
AR125079A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas de receptores de glucocorticoides sustituidos con carboxi
TW202304462A (zh) * 2021-03-23 2023-02-01 美商美國禮來大藥廠 糖皮質素受體激動劑
WO2022268176A1 (zh) * 2021-06-24 2022-12-29 江苏先声药业有限公司 甾体类化合物、其药物组合物及其应用
WO2023025248A1 (zh) * 2021-08-26 2023-03-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
TW202327620A (zh) * 2021-09-14 2023-07-16 大陸商映恩生物製藥（蘇州）有限公司 一種抗炎症的化合物及其用途
WO2023245106A1 (en) * 2022-06-16 2023-12-21 Abbvie Biotherapeutics Inc. Anti-cd19 antibody drug conjugates
WO2024020164A2 (en) 2022-07-21 2024-01-25 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
WO2024064779A1 (en) * 2022-09-22 2024-03-28 Eli Lilly And Company Glucocorticoid receptor agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2399945T3 (es) * 2007-11-30 2013-04-04 Pfizer Limited Agonistas novedosos de los receptores de glucocorticoides
CA2710149A1 (en) * 2007-12-21 2009-07-09 John C. Anthes C20-c21 substituted glucocorticoid receptor agonists
MX339239B (es) * 2011-04-29 2016-05-18 Apexigen Inc Anticuerpos anti-cd40 y metodos de uso.
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
WO2015153401A1 (en) * 2014-04-04 2015-10-08 Merck Sharp & Dohme Corp Phosphate based linkers for intracellular delivery of drug conjugates
CA2987051A1 (en) * 2015-05-29 2016-12-08 Abbvie Inc. Anti-cd40 antibodies and uses thereof

Also Published As

Publication number Publication date
EP3716982A1 (en) 2020-10-07
CL2020001442A1 (es) 2020-09-11
RU2020117156A (ru) 2022-01-04
IL274650A (en) 2020-06-30
SG11202004865SA (en) 2020-06-29
KR20200095493A (ko) 2020-08-10
DOP2020000119A (es) 2020-08-31
JP2021504430A (ja) 2021-02-15
AU2018374633A1 (en) 2020-05-21
US20220265842A1 (en) 2022-08-25
WO2019106608A1 (en) 2019-06-06
MX2020005465A (es) 2020-09-07
CR20200285A (es) 2020-09-04
BR112020010691A2 (pt) 2020-11-10
CN111465399A (zh) 2020-07-28
PE20201464A1 (es) 2020-12-17
EP3716982A4 (en) 2021-08-11
CA3081559A1 (en) 2019-06-06
PH12020550551A1 (en) 2021-03-22

Similar Documents

Publication Publication Date Title
ECSP20034868A (es) Conjugados anticuerpo anti-cd40-fármaco
CL2021001706A1 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos (divisional de solicitud no. 201900326)
CL2020000263A1 (es) Conjugado de anticuerpo monoclonal contra bcma-fármaco.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
EA201990615A1 (ru) Пирролобензодиазепиновые конъюгаты
UY38140A (es) Picolinamidas como fungicidas
EA201791550A1 (ru) Димеры бензодиазепинов, их конъюгаты и способы их получения и применения
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
CL2019001740A1 (es) Novedoso conjugado de amanitina.
CO2017004782A2 (es) Conjugados de anticuerpo- farmaco
DOP2017000202A (es) Desacetoxitubulisina h y análogos de esta
CR20190268A (es) Nuevos deribados de isoxazolil éter como pam de gaba a alfa5
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
BR112021015477A2 (pt) Anticorpos anti-cd228 e conjugados anticorpo-fármaco
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
ECSP21068097A (es) Anticuerpos claudina 6 y usos de los mismos
CL2021001308A1 (es) Derivados de bis-octahidrofenantreno carboxamida y conjugados de proteína de los mismos para su uso como agonistas de lxr.
CL2023000894A1 (es) Compuestos de heteroarilo fusionados y su uso como inhibidores de camkii
UY38759A (es) Tienilhidroxiisoxazolinas y derivados de las mismas
CO2019013718A2 (es) Anticuerpos anti-trkb
BR112021011124A2 (pt) Anelossomos e métodos de uso
CO2022003742A2 (es) Conjugados de interleuquina 10 y sus usos
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso